1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • May 2017
  • 280 pages
  • ID: 5012992
  • Format: PDF
  • GlobalData
Up to $8246 off Until May 31st 2020

Summary

Table of Contents

Search Inside

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Summary
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological cancers. Due to the non-specific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point their prognosis is poor. Current standard of care (SOC) therapies focus on primary de-bulking surgery, followed by adjuvant platinum-based chemotherapy or neoadjuvant platinum-based chemotherapy, followed by interval de-bulking surgery and additional cycles of platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard.

In 2015, the total ovarian cancer market was valued at US$1.233B across the 7MM, with the US accounting for 47.2% of the market. Over the course of the forecast period (till 2025), GlobalData expects the 7MM sales to dramatically increase at a Compound Annual Growth Rate (CAGR) of 15%+.

The key driver of growth within the 7MM ovarian cancer market will be the establishment of new standard of care (SOC) maintenance therapies in the first and second lines of treatment for newly diagnosed and recurrent patients. The anticipated extended durations of therapy in the maintenance settings should fuel the sales of PARP inhibitors and immune checkpoint modulators, as their efficacy data is expected to justify their expensive price tags.

Major drivers of growth in the ovarian cancer market across the 7MM also include the following -
- Embracing PARP inhibitors into the treatment paradigm of patients will drive growth in the ovarian cancer market, especially through the provision of a targeted therapy option for patients leading to a more personalized approach to disease treatment.
- A significant contributor to growth in the ovarian cancer market will be the adoption of IO drugs in the treatment of the disease as the paradigm shifts toward treatment choices based on the individual patient.
- The adoption of maintenance therapy will result in patients receiving drugs for a longer duration, thereby increasing the longevity of product sales compared to those products isolated in the later lines of therapy.

The report "OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025" provides an overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following analysis -
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AB Science,AbbVie, Acerta, Aprea, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celsion, Chugai Pharmaceutical, Clovis Oncology, Ganymed, Genentech, Gradalis, ImmunoGen, Immunovaccine, Incyte, Innate Pharma, Janssen, Mateon Therapeutics, MedImmune, Merck & Co., Merck KGaA, Oasmia, Oncolytics Biotech, Ono Phamaceutical, Pfizer, PharmaMar, Prima BioMed, PsiOxus Therapeutics, Roche, Sotio, Taiho Pharmaceutical, Tesaro, VentiRx

Scope
- Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Oligodendroglioma - Pipeline Review, H1 2020

  • $ 2000
  • March 2020
  • 156 pages

Oligodendroglioma - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H1 2020, provides an overview of the Oligodendroglioma ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on